Lung Cancer
A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)
- Details
ClinicalTrials.gov ID:
NCT02954991
Diagnosis Type:
NSCLC
USOR Number:
- Address
,
P: